USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Asia-Pacific Next-generation Diagnostics Outlook, 2023
Asia-Pacific Next-generation Diagnostics Outlook, 2023
The Renewed Focus on Infectious Diseases Outside COVID-9, Oncology, Cardiovascular, Diabetes, and Prenatal Care will Drive Market Growth
20-Apr-2023
Asia Pacific
$4,950.00
Special Price $4,455.00 save 10 %
Description
The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus on breakthrough innovation, diagnostic services must be revamped to meet reduced price points for low-resource settings.
The pandemic led to a greater focus on preventive diagnosis. Innovation in product development, a focus on care delivery and business models, and the need for more convenient sampling are leading to a paradigm shift to minimally invasive tests. Global IVD powerhouses remain at the vanguard of this transformation. Prominent market participants are Roche Diagnostics, Abbott Laboratories, Danaher Corporation, Siemens Healthineers, and Sysmex Corporation, while regional IVD powerhouses are making a strategic shift to leverage the platform-as-a-service business model, implying momentum in secured and connected open development platforms to support rapid and standardized assay development. Trends point toward a focus on infectious diseases outside COVID-19, molecular oncology, cardiovascular disease, and diabetes, with an emerging focus on noninvasive prenatal testing (NIPT).
Author: Amartya Bose
Table of Contents
Study Highlights
Top Next-generation Diagnostics Industry Predictions—2023
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Next-generation Diagnostics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Segmentation
Growth Environment
Top 5 Global Economic Highlights—2023
Global GDP Growth Snapshot
Advanced Economies’ Predictions—2023
Emerging Economies’ Predictions—2023
Regional Risks and Policy Direction—2023
Supply Chain Disruptions—Impact Analysis
Innovation—Impact Analysis
Commercial Success—Impact Analysis
Revenue Forecast by Segment
Revenue Forecast by Segment (continued)
Competitive Environment
Revenue Share
Revenue Share Analysis
Revenue Forecast by Country
Revenue Forecast Analysis by Country
Prediction 1—Infectious Disease Testing will Largely Transition to POC Rapid Tests
Prediction 2—Comprehensive POCT Solutions in Diabetes Care will Proliferate to Empower Fast Clinical Decision Making
Prediction 3—A Spike in Population-sequencing Efforts will Drive NGS Market Expansion
Prediction 4—Demand for Cardiac Biomarker Testing in Hospitals will Drive Clinical Chemistry and Immunoassay Market Growth in China
Market Snapshot—2023
Market Snapshot—Clinical Chemistry and Immunoassays
Market Snapshot—Molecular Diagnostics
Market Snapshot—POCT
Growth Opportunity 1: POC Rapid Testing
Growth Opportunity 1: POC Rapid Testing (continued)
Growth Opportunity 2: NIPT
Growth Opportunity 2: NIPT (continued)
Growth Opportunity 3: Comprehensive Cancer Genomic Profiling Services
Growth Opportunity 3: Comprehensive Cancer Genomic Profiling Services (continued)
Conclusion
Your Next Steps
Why Frost, Why Now?
List of Exhibits
Legal Disclaimer
Popular Topics
| Author | Amartya Bose |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Next-Generation Diagnostics Market |
| Keyword 2 | Ivd Market |
| Keyword 3 | In-Vitro Diagnostics Market |
| Podcast | No |
| WIP Number | PE5C-01-00-00-00 |